FDA shares vascular guidewire warning due to safety risk

The U.S. Food and Drug Administration (FDA) is warning the public about a new recall involving specific lots of multiple vascular guidewires. 

The devices in question are the Navilyst Vascular Guidewire, Spectrum Vascular Guidewire and Arrow Marked Guidewire manufactured by Minnesota-based Heraeus Medevio. They were built to help interventional cardiologists, interventional radiologists and other clinicians enter a patient’s peripheral blood vessels during minimally invasive procedures. 

This is an Early Alert communication, which means the FDA is still reviewing the issue. Once its investigation is done, the agency will confirm the severity of this recall.  

The reason behind this alert

Heraeus Medevio, previously known as Heraeus Medical Components, identified a risk of the coating on these guidewires swelling in a way that could harm a patient. No adverse events have been reported, but the FDA is urging customers to remove these devices from where they are used and sold.

“The hydrophilic coating on the guidewire has the potential to swell inconsistently when hydrated with saline leading to clumping of the coating,” according to the FDA’s advisory. “This occurs most frequently on the distal coil section of the guidewire. When clumping occurs, there is increased potential for hydrophilic coating flaking, displacement or detachment. This could result in particle release entering the blood stream of the patient and could lead to a thromboembolic event, depending on the size and quantity of the particles released.”

Subscribe to Cardiovascular Business News

What customers need to know

The affected devices include:

Navilyst Vascular Guidewire

  • H965457461
  • H965457471

Spectrum Vascular Guidewire

  • H965457461
  • H965457471

Arrow Marked Guidewire

  • PW-18080-HN 
  • PW-16130-HN

Heraeus Medevio is urging customers to review their inventories and immediately stop the use of these devices. Any companies that have distributed these guidewires should notify their customers right away.  

“The FDA is currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available,” according to the agency.

Click here for more details.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News